Praxis Precision Medicines (PRAX) Competitors $39.70 +2.35 (+6.29%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. CRNX, ALVO, SRRK, MRUS, ACAD, CPRX, MOR, PTGX, MTSR, and XENEShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Scholar Rock (SRRK), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), Protagonist Therapeutics (PTGX), Metsera (MTSR), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Crinetics Pharmaceuticals Alvotech Scholar Rock Merus ACADIA Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics Metsera Xenon Pharmaceuticals Crinetics Pharmaceuticals (NASDAQ:CRNX) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations. Which has higher earnings and valuation, CRNX or PRAX? Praxis Precision Medicines has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$760K3,864.66-$214.53M-$3.82-8.21Praxis Precision Medicines$8.12M99.56-$123.28M-$10.72-3.70 Do institutionals and insiders believe in CRNX or PRAX? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is CRNX or PRAX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -36.12% -31.89% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Does the MarketBeat Community favor CRNX or PRAX? Crinetics Pharmaceuticals received 106 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 74.65% of users gave Praxis Precision Medicines an outperform vote while only 69.43% of users gave Crinetics Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCrinetics PharmaceuticalsOutperform Votes15969.43% Underperform Votes7030.57% Praxis Precision MedicinesOutperform Votes5374.65% Underperform Votes1825.35% Does the media prefer CRNX or PRAX? In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 15 mentions for Crinetics Pharmaceuticals and 10 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.46 beat Crinetics Pharmaceuticals' score of 0.99 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CRNX or PRAX? Crinetics Pharmaceuticals presently has a consensus target price of $73.00, suggesting a potential upside of 132.71%. Praxis Precision Medicines has a consensus target price of $116.50, suggesting a potential upside of 193.45%. Given Praxis Precision Medicines' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, CRNX or PRAX? Crinetics Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. SummaryCrinetics Pharmaceuticals beats Praxis Precision Medicines on 11 of the 18 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$808.65M$6.55B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-3.859.1426.8320.05Price / Sales99.56255.59393.86117.02Price / CashN/A65.8538.2534.62Price / Book5.016.546.874.61Net Income-$123.28M$143.51M$3.22B$248.19M7 Day Performance6.38%4.66%5.65%2.88%1 Month Performance17.49%10.63%13.54%15.40%1 Year Performance-11.80%-1.05%18.16%7.68% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines3.2197 of 5 stars$39.70+6.3%$116.50+193.5%-17.7%$808.65M$8.12M-3.85110CRNXCrinetics Pharmaceuticals3.7084 of 5 stars$33.32+8.6%$73.00+119.1%-39.8%$3.12B$1.04M-8.93210ALVOAlvotech1.8072 of 5 stars$10.25+5.9%$18.00+75.6%-25.4%$3.09B$489.68M-5.544High Trading VolumeSRRKScholar Rock4.0519 of 5 stars$32.46+5.8%$42.67+31.4%+141.5%$3.08B$33.19M-13.81140Earnings ReportAnalyst RevisionMRUSMerus3.2633 of 5 stars$42.41+3.7%$85.15+100.8%-5.8%$2.94B$36.13M-10.7437Earnings ReportAnalyst ForecastACADACADIA Pharmaceuticals3.2996 of 5 stars$17.52+0.5%$24.70+41.0%+48.7%$2.93B$957.80M22.46510Trending NewsAnalyst ForecastCPRXCatalyst Pharmaceuticals4.6593 of 5 stars$23.83+2.0%$32.29+35.5%+49.4%$2.91B$534.65M20.1980Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.3014 of 5 stars$45.27+5.4%$65.44+44.6%+48.2%$2.80B$207.80M17.02120Analyst ForecastMTSRMetseraN/A$26.38+10.5%$47.00+78.2%N/A$2.77BN/A0.0081XENEXenon Pharmaceuticals3.2784 of 5 stars$35.85+2.4%$56.22+56.8%-22.2%$2.75B$9.43M-12.71210High Trading Volume Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors Alvotech Competitors Scholar Rock Competitors Merus Competitors ACADIA Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors MorphoSys Competitors Protagonist Therapeutics Competitors Metsera Competitors Xenon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRAX Stock Free PRAX Stock Alerts